Trial Profile
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Synthetic vaccines (Primary) ; Poly ICLC; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions
- 09 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 28 Sep 2022 Planned End Date changed from 31 Jan 2029 to 24 Sep 2025.
- 28 Sep 2022 Status changed from suspended to active, no longer recruiting.